
Opinion|Videos|August 29, 2024
Role of Multidisciplinary Team & Logistics of CAR T-cell Therapy Administration in the Inpatient or Outpatient Setting
Key opinion leaders address the availability of brexucabtagene autoleucel (brexu-cel) at their institutions and outline procedures for ensuring risk evaluation and mitigation strategy compliance and comprehensive training across multidisciplinary teams.
Advertisement
Video content above is prompted by the following:
- For those who have brexu-cel on-formulary or available at your institution, what processes did you and your team take to ensure REMS compliance and training among multidisciplinary team members?
- Typically, is a physician, pharmacist, nurse, quality coordinator or another member of the team the REMS Authorized Representative?
- At your institution, are patients receiving CAR-T cell Therapy in the outpatient or inpatient setting?
- For those infusing CAR-T cell Therapy in the outpatient setting, how are patients being monitored?
Advertisement
Related to this article

ASCO issued an alert regarding dwindling supplies of ifosfamide, which is used across testicular cancer and sarcoma regimens.

The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.

The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.

The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.

Ivonescimab plus chemotherapy significantly improved overall survival vs durvalumab plus chemotherapy in advanced biliary tract cancer.

The pertuzumab biosimilar TQB2440 met equivalence margins for tpCR vs reference pertuzumab in ER/PR-negative, HER2-positive early breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5


